Loading…
Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells
Background Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (...
Saved in:
Published in: | Communications medicine 2024-09, Vol.4 (1), p.187-14, Article 187 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3 |
container_end_page | 14 |
container_issue | 1 |
container_start_page | 187 |
container_title | Communications medicine |
container_volume | 4 |
creator | Ishida, Masaaki Masuda, Tomohiro Sakai, Noriko Nakai-Futatsugi, Yoko Kamao, Hiroyuki Shiina, Takashi Takahashi, Masayo Sugita, Sunao |
description | Background
Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (MHC-II) molecules, we hypothesized immune rejection could be evaded by suppressing MHC-II.
Methods
Gene editing by the Crispr/Cas9 system was performed in induced pluripotent stem cells derived from a cynomolgus monkey (miPSCs) for targeted deletion of the gene coding
class II MHC trans-activator
(
CIITA
). Then the
CIITA
-knocked out miPSCs were differentiated into RPE cells to generate miPSC-derived MHC-II knockout RPE. The MHC-II knockout or wild-type RPEs were transplanted into the eyes of healthy cynomolgus monkeys. All monkeys used in this study were male.
Results
Here we show when MHC-II knockout RPE are transplanted into monkey eyes, they show suppressed immunogenicity with no infiltration of inflammatory cells, leading to successful engraftment.
Conclusions
Our results reasonably evidence the efficacy of MHC-II knockout iPSC-RPE transplants for clinical application.
Plain language summary
Transplantation of healthy cells can be used to treat irreversibly damaged organs. However, a concern is that the transplanted cells will be rejected by the immune system. Generally, the immune system protects our body when unknown materials invade. But this is undesirable during cell transplantation as the transplanted cells are often eliminated by the host’s immune cells. We demonstrated in monkeys that deletion of part of the immune system in cells prior to transplantation reduced the amount of immune system activity following transplantation. Using similar strategies in the future could enable cell transplants to be used more successfully in humans, making cell transplantation therapy safer and applicable to a wider number of patients.
Ishida et al. transplant Crispr/Cas9 gene edited MHC-II knockout or wild-type retinal pigment epithelium into cynomolgus monkey eyes. MHC-II knockout RPE engraft successfully with no infiltration of inflammatory cells. |
doi_str_mv | 10.1038/s43856-024-00617-5 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b0c88034134c424f9b2a5f55be3f201b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b0c88034134c424f9b2a5f55be3f201b</doaj_id><sourcerecordid>3111635327</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhi0EotXSP8ABReLCJeDvOCeEKiiVKnFppR6QLNsZb71K4sVOVvTf4zSltBx6sj3zzjOeD4TeEvyRYKY-Zc6UkDWmvMZYkqYWL9AxbRiupeTXLx_dj9BJzjuMMW1kyxV-jY5Yy3grVHOMfp4l46cqz-kQDqavoq8Gs4upugl5ii4OezMFG_ow3VbLq4ffVQc-uABjCZtgqBz0fd1BCgfoqgRTGAtnMeY36JU3fYaT-3ODrr59vTz9Xl_8ODs__XJRO07pVDvTMcCulZwKUK6RrrHAObZeNZa3XdNiokB5RfDyYFJQSjuOO2uZcQrYBp2v3C6and6nMJh0q6MJ-s4Q01abNAXXg7bYKYUZJ4yX5Ny3lhrhhbDAPMXEFtbnlbWf7QCdK2Um0z-BPvWM4UZv40ETwjmVLSmED_eEFH_NkCc9hLz0w4wQ56wZIUQywcqANuj9f9JdnFPp36oqlRK-qOiqcinmnMA__IZgvSyDXpdBl2XQd8ugRQl697iOh5C_oy8CtgpycY1bSP9yP4P9AxNmwKM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111365147</pqid></control><display><type>article</type><title>Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Ishida, Masaaki ; Masuda, Tomohiro ; Sakai, Noriko ; Nakai-Futatsugi, Yoko ; Kamao, Hiroyuki ; Shiina, Takashi ; Takahashi, Masayo ; Sugita, Sunao</creator><creatorcontrib>Ishida, Masaaki ; Masuda, Tomohiro ; Sakai, Noriko ; Nakai-Futatsugi, Yoko ; Kamao, Hiroyuki ; Shiina, Takashi ; Takahashi, Masayo ; Sugita, Sunao</creatorcontrib><description>Background
Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (MHC-II) molecules, we hypothesized immune rejection could be evaded by suppressing MHC-II.
Methods
Gene editing by the Crispr/Cas9 system was performed in induced pluripotent stem cells derived from a cynomolgus monkey (miPSCs) for targeted deletion of the gene coding
class II MHC trans-activator
(
CIITA
). Then the
CIITA
-knocked out miPSCs were differentiated into RPE cells to generate miPSC-derived MHC-II knockout RPE. The MHC-II knockout or wild-type RPEs were transplanted into the eyes of healthy cynomolgus monkeys. All monkeys used in this study were male.
Results
Here we show when MHC-II knockout RPE are transplanted into monkey eyes, they show suppressed immunogenicity with no infiltration of inflammatory cells, leading to successful engraftment.
Conclusions
Our results reasonably evidence the efficacy of MHC-II knockout iPSC-RPE transplants for clinical application.
Plain language summary
Transplantation of healthy cells can be used to treat irreversibly damaged organs. However, a concern is that the transplanted cells will be rejected by the immune system. Generally, the immune system protects our body when unknown materials invade. But this is undesirable during cell transplantation as the transplanted cells are often eliminated by the host’s immune cells. We demonstrated in monkeys that deletion of part of the immune system in cells prior to transplantation reduced the amount of immune system activity following transplantation. Using similar strategies in the future could enable cell transplants to be used more successfully in humans, making cell transplantation therapy safer and applicable to a wider number of patients.
Ishida et al. transplant Crispr/Cas9 gene edited MHC-II knockout or wild-type retinal pigment epithelium into cynomolgus monkey eyes. MHC-II knockout RPE engraft successfully with no infiltration of inflammatory cells.</description><identifier>ISSN: 2730-664X</identifier><identifier>EISSN: 2730-664X</identifier><identifier>DOI: 10.1038/s43856-024-00617-5</identifier><identifier>PMID: 39349587</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13 ; 13/107 ; 631/250/1854/2812 ; 631/532/489 ; Antibodies ; Antigens ; Cell culture ; Immunohistochemistry ; Laboratory animals ; Macular degeneration ; Medicine ; Medicine & Public Health ; Stem cells ; Transplants & implants</subject><ispartof>Communications medicine, 2024-09, Vol.4 (1), p.187-14, Article 187</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3</cites><orcidid>0000-0003-4187-6060 ; 0000-0002-2067-6708</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3111365147/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3111365147?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39349587$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishida, Masaaki</creatorcontrib><creatorcontrib>Masuda, Tomohiro</creatorcontrib><creatorcontrib>Sakai, Noriko</creatorcontrib><creatorcontrib>Nakai-Futatsugi, Yoko</creatorcontrib><creatorcontrib>Kamao, Hiroyuki</creatorcontrib><creatorcontrib>Shiina, Takashi</creatorcontrib><creatorcontrib>Takahashi, Masayo</creatorcontrib><creatorcontrib>Sugita, Sunao</creatorcontrib><title>Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells</title><title>Communications medicine</title><addtitle>Commun Med</addtitle><addtitle>Commun Med (Lond)</addtitle><description>Background
Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (MHC-II) molecules, we hypothesized immune rejection could be evaded by suppressing MHC-II.
Methods
Gene editing by the Crispr/Cas9 system was performed in induced pluripotent stem cells derived from a cynomolgus monkey (miPSCs) for targeted deletion of the gene coding
class II MHC trans-activator
(
CIITA
). Then the
CIITA
-knocked out miPSCs were differentiated into RPE cells to generate miPSC-derived MHC-II knockout RPE. The MHC-II knockout or wild-type RPEs were transplanted into the eyes of healthy cynomolgus monkeys. All monkeys used in this study were male.
Results
Here we show when MHC-II knockout RPE are transplanted into monkey eyes, they show suppressed immunogenicity with no infiltration of inflammatory cells, leading to successful engraftment.
Conclusions
Our results reasonably evidence the efficacy of MHC-II knockout iPSC-RPE transplants for clinical application.
Plain language summary
Transplantation of healthy cells can be used to treat irreversibly damaged organs. However, a concern is that the transplanted cells will be rejected by the immune system. Generally, the immune system protects our body when unknown materials invade. But this is undesirable during cell transplantation as the transplanted cells are often eliminated by the host’s immune cells. We demonstrated in monkeys that deletion of part of the immune system in cells prior to transplantation reduced the amount of immune system activity following transplantation. Using similar strategies in the future could enable cell transplants to be used more successfully in humans, making cell transplantation therapy safer and applicable to a wider number of patients.
Ishida et al. transplant Crispr/Cas9 gene edited MHC-II knockout or wild-type retinal pigment epithelium into cynomolgus monkey eyes. MHC-II knockout RPE engraft successfully with no infiltration of inflammatory cells.</description><subject>13</subject><subject>13/107</subject><subject>631/250/1854/2812</subject><subject>631/532/489</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Cell culture</subject><subject>Immunohistochemistry</subject><subject>Laboratory animals</subject><subject>Macular degeneration</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Stem cells</subject><subject>Transplants & implants</subject><issn>2730-664X</issn><issn>2730-664X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1v1DAQhi0EotXSP8ABReLCJeDvOCeEKiiVKnFppR6QLNsZb71K4sVOVvTf4zSltBx6sj3zzjOeD4TeEvyRYKY-Zc6UkDWmvMZYkqYWL9AxbRiupeTXLx_dj9BJzjuMMW1kyxV-jY5Yy3grVHOMfp4l46cqz-kQDqavoq8Gs4upugl5ii4OezMFG_ow3VbLq4ffVQc-uABjCZtgqBz0fd1BCgfoqgRTGAtnMeY36JU3fYaT-3ODrr59vTz9Xl_8ODs__XJRO07pVDvTMcCulZwKUK6RrrHAObZeNZa3XdNiokB5RfDyYFJQSjuOO2uZcQrYBp2v3C6and6nMJh0q6MJ-s4Q01abNAXXg7bYKYUZJ4yX5Ny3lhrhhbDAPMXEFtbnlbWf7QCdK2Um0z-BPvWM4UZv40ETwjmVLSmED_eEFH_NkCc9hLz0w4wQ56wZIUQywcqANuj9f9JdnFPp36oqlRK-qOiqcinmnMA__IZgvSyDXpdBl2XQd8ugRQl697iOh5C_oy8CtgpycY1bSP9yP4P9AxNmwKM</recordid><startdate>20240930</startdate><enddate>20240930</enddate><creator>Ishida, Masaaki</creator><creator>Masuda, Tomohiro</creator><creator>Sakai, Noriko</creator><creator>Nakai-Futatsugi, Yoko</creator><creator>Kamao, Hiroyuki</creator><creator>Shiina, Takashi</creator><creator>Takahashi, Masayo</creator><creator>Sugita, Sunao</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4187-6060</orcidid><orcidid>https://orcid.org/0000-0002-2067-6708</orcidid></search><sort><creationdate>20240930</creationdate><title>Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells</title><author>Ishida, Masaaki ; Masuda, Tomohiro ; Sakai, Noriko ; Nakai-Futatsugi, Yoko ; Kamao, Hiroyuki ; Shiina, Takashi ; Takahashi, Masayo ; Sugita, Sunao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>13</topic><topic>13/107</topic><topic>631/250/1854/2812</topic><topic>631/532/489</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Cell culture</topic><topic>Immunohistochemistry</topic><topic>Laboratory animals</topic><topic>Macular degeneration</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Stem cells</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishida, Masaaki</creatorcontrib><creatorcontrib>Masuda, Tomohiro</creatorcontrib><creatorcontrib>Sakai, Noriko</creatorcontrib><creatorcontrib>Nakai-Futatsugi, Yoko</creatorcontrib><creatorcontrib>Kamao, Hiroyuki</creatorcontrib><creatorcontrib>Shiina, Takashi</creatorcontrib><creatorcontrib>Takahashi, Masayo</creatorcontrib><creatorcontrib>Sugita, Sunao</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medicine (ProQuest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database (ProQuest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Health Management Database (ProQuest)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Communications medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishida, Masaaki</au><au>Masuda, Tomohiro</au><au>Sakai, Noriko</au><au>Nakai-Futatsugi, Yoko</au><au>Kamao, Hiroyuki</au><au>Shiina, Takashi</au><au>Takahashi, Masayo</au><au>Sugita, Sunao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells</atitle><jtitle>Communications medicine</jtitle><stitle>Commun Med</stitle><addtitle>Commun Med (Lond)</addtitle><date>2024-09-30</date><risdate>2024</risdate><volume>4</volume><issue>1</issue><spage>187</spage><epage>14</epage><pages>187-14</pages><artnum>187</artnum><issn>2730-664X</issn><eissn>2730-664X</eissn><abstract>Background
Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (MHC-II) molecules, we hypothesized immune rejection could be evaded by suppressing MHC-II.
Methods
Gene editing by the Crispr/Cas9 system was performed in induced pluripotent stem cells derived from a cynomolgus monkey (miPSCs) for targeted deletion of the gene coding
class II MHC trans-activator
(
CIITA
). Then the
CIITA
-knocked out miPSCs were differentiated into RPE cells to generate miPSC-derived MHC-II knockout RPE. The MHC-II knockout or wild-type RPEs were transplanted into the eyes of healthy cynomolgus monkeys. All monkeys used in this study were male.
Results
Here we show when MHC-II knockout RPE are transplanted into monkey eyes, they show suppressed immunogenicity with no infiltration of inflammatory cells, leading to successful engraftment.
Conclusions
Our results reasonably evidence the efficacy of MHC-II knockout iPSC-RPE transplants for clinical application.
Plain language summary
Transplantation of healthy cells can be used to treat irreversibly damaged organs. However, a concern is that the transplanted cells will be rejected by the immune system. Generally, the immune system protects our body when unknown materials invade. But this is undesirable during cell transplantation as the transplanted cells are often eliminated by the host’s immune cells. We demonstrated in monkeys that deletion of part of the immune system in cells prior to transplantation reduced the amount of immune system activity following transplantation. Using similar strategies in the future could enable cell transplants to be used more successfully in humans, making cell transplantation therapy safer and applicable to a wider number of patients.
Ishida et al. transplant Crispr/Cas9 gene edited MHC-II knockout or wild-type retinal pigment epithelium into cynomolgus monkey eyes. MHC-II knockout RPE engraft successfully with no infiltration of inflammatory cells.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>39349587</pmid><doi>10.1038/s43856-024-00617-5</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-4187-6060</orcidid><orcidid>https://orcid.org/0000-0002-2067-6708</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2730-664X |
ispartof | Communications medicine, 2024-09, Vol.4 (1), p.187-14, Article 187 |
issn | 2730-664X 2730-664X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_b0c88034134c424f9b2a5f55be3f201b |
source | Publicly Available Content Database; PubMed Central; Alma/SFX Local Collection; Springer Nature - nature.com Journals - Fully Open Access |
subjects | 13 13/107 631/250/1854/2812 631/532/489 Antibodies Antigens Cell culture Immunohistochemistry Laboratory animals Macular degeneration Medicine Medicine & Public Health Stem cells Transplants & implants |
title | Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Graft%20survival%20of%20major%20histocompatibility%20complex%20deficient%20stem%20cell-derived%20retinal%20cells&rft.jtitle=Communications%20medicine&rft.au=Ishida,%20Masaaki&rft.date=2024-09-30&rft.volume=4&rft.issue=1&rft.spage=187&rft.epage=14&rft.pages=187-14&rft.artnum=187&rft.issn=2730-664X&rft.eissn=2730-664X&rft_id=info:doi/10.1038/s43856-024-00617-5&rft_dat=%3Cproquest_doaj_%3E3111635327%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3111365147&rft_id=info:pmid/39349587&rfr_iscdi=true |